Tag: Therapeutics
Viking Therapeutics stock jumps on weight loss injection trial plans
Weight loss drug concept.Cr | Istock | Getty ImagesShares of Viking Therapeutics jumped 28% on Thursday after the biotech company a day earlier announ [...]
Viking Therapeutics weight loss pill shows positive study results
Alexey Krukovsky | Istock | Getty ImagesViking Therapeutics shares jumped more than 25% on Tuesday after the company said its experimental weight loss [...]
Viking Therapeutics emerges as competitor
Cr | Istock | Getty ImagesBiotech company Viking Therapeutics has emerged as a strong potential entrant — or takeover target — in the budding weight l [...]
Viking Therapeutics weight loss drug shows promising trial results
Cr | Istock | Getty ImagesShares of Viking Therapeutics soared about 80% on Tuesday after the company's experimental weight loss drug showed promising [...]
Bristol Myers Squibb to buy Karuna Therapeutics
Bristol Myers Squibb on Friday announced it agreed to buy biopharmaceutical company Karuna Therapeutics for $14 billion in cash, or $330 per share.Kar [...]
AbbVie to acquire Cerevel Therapeutics for $8.7 billion
A sign stands outside a Abbvie facility in Cambridge, Massachusetts, May 20, 2021.Brian Snyder | ReutersAbbVie on Wednesday said it will acquire neuro [...]
Flare Therapeutics Presents New Translational Data in Support of Lead Asset FX-909 for the Treatment of Muscle-Invasive Urothelial Cancer at SITC 2023 Annual Meeting
--Poster presentation proposes targeting PPARG for the treatment of muscle-invasive urothelial cancer (MIUC) may help overcome resistance to immunoth [...]
Flare Therapeutics Presents Novel, AI-Based Method Identifying Luminal Subtype of Urothelial Cancer Supporting Lead Asset FX-909 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
– Approach has potential to identify patients likely to respond to PPARG inhibition through FX-909 –
– AI-powered, end-to-end learning model was deve [...]
Flare Therapeutics to Present Biomarker Data for Clinical Candidate FX-909 at 2023 AACR-NCI-EORTC International Conference
CAMBRIDGE, Mass., Oct. 4, 2023 /PRNewswire/ -- Flare Therapeutics Inc., a biotechnology company targeting transcription factors to discover precision [...]
Obesity pill data boosts Structure Therapeutics shares
Aykut Karahan | Istock | Getty ImagesShares of Structure Therapeutics rose more than 30% on Friday after the biotech startup's experimental obesity [...]
FTC allows Amgen Horizon Therapeutics deal to move forward
The Amgen logo is displayed outside Amgen headquarters on May 17, 2023 in Thousand Oaks, California.Mario Tama | Getty ImagesThe Federal Trade Commiss [...]
Sage Therapeutics plunges after FDA decision on depression drug
In this photo illustration, the Sage Therapeutics logo of a biopharmaceutical company seen on a smartphone and on a pc screen.Pavlo Gonchar | SOPA Ima [...]
Eli Lilly to acquire Dice Therapeutics for $2.4 billion
David Ricks, CEO, Eli LillyScott Mlyn | CNBCEli Lilly on Tuesday said it struck a $2.4 billion deal to acquire Dice Therapeutics in a bid to bulk up i [...]
FTC preparing to block Amgen-Horizon Therapeutics deal, report says
Robert Galbraith | ReutersHorizon Therapeutics' stock price plunged more than 17% in premarket trading Tuesday after a report that the Federal Trade C [...]
Flare Therapeutics Presents First Preclinical Data on Lead Asset FX-909, a Novel Small Molecule PPARG Inhibitor to Potentially Treat Urothelial Cancer, at the 2023 AACR Annual Meeting
--FX-909 is highly potent and selective for the PPARG transcription factor, and demonstrates tumor eradication in preclinical animal models of urothel [...]